COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Saber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Improvement, RR [CI]TreatmentControlPawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.00; I​2 = 0.0%Early treatment86%0.14 [0.04-0.47]2/12122/12086% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies71%0.29 [0.13-0.63]6/14130/14071% improvement4 curcumin COVID-19 studiesc19curcumin.com 7/25/21Tau​2 = 0.00; I​2 = 0.0%; Z = 3.11 (p = 0.00094)Effect extraction pre-specifiedLower RiskIncreased Risk
7/9
Early Panda et al., Medicine, doi:10.1097/MD.0000000000026601 (Peer Reviewed) The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
Details   Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability.
6/29
In Vitro Guijarro-Real et al., Foods, doi:10.3390/foods10071503 (Peer Reviewed) (In Vitro) in vitro Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
Details   In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLPro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLPro activity, but did not fully account for the inhibitory effect of turmeric rh..
6/19
Early Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 (Peer Reviewed) hosp., ↓85.7%, p=0.24 Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
Details   RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
5/28
Early Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 (Peer Reviewed) death, ↓81.8%, p=0.02 Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Details   RCT 140 patients, 70 treated with curcumin and piperine (for absorption), showing faster recovery, lower progression, and lower mortality with treatment. Control group partients also received probiotics. CTRI/2020/05/025482.
5/7
Review Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review) (Peer Reviewed) review Curcumin as a Potential Treatment for COVID-19
Details   Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects.
1/3
Early Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 (Peer Reviewed) progression, ↓94.3%, p=0.001 Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
Details   Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
10/20
Late Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 (Peer Reviewed) death, ↓50.0%, p=0.30 Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Details   Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit